Metacognitive therapy for Generalized Anxiety Disorder in patients with a schizophrenia-spectrum disorder
- Conditions
- generalised anxiety disorderpsychosisschizophrenia-spectrum disorderworrying10039628
- Registration Number
- NL-OMON49487
- Lead Sponsor
- Parnassia Bavo Groep (Den Haag)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 9
1. Age between 18-65;
2. primary diagnosis of schizophrenia-spectrum disorder according to DSM-5
3. A score of 10 or higher on the GAD-7, a diagnostic screening list for GAD
4. A clinically significant degree of worrying, shown by a high score (* 49) on
the Penn State Worry Questionnaire
5. In case of intended radical changes in the field of pharmacotherapy,
patients can only enter the study if the dose is stable for at least one month.
Patients are excluded when:
1. they are unable or seem unable to give informed consent;
2. they don't sufficiently master the dutch language to undergo treatment
without an interpreter
3. there is alcohol or drug abuse that interferes with treatment
4. they have an IQ of 70 or below
5. they have an organic disorder
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method